Summit Therapeutics (SMMT) Income from Continuing Operations (2016 - 2024)
Historic Income from Continuing Operations for Summit Therapeutics (SMMT) over the last 8 years, with Q4 2024 value amounting to -$65.6 million.
- Summit Therapeutics' Income from Continuing Operations fell 8122.89% to -$65.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$183.2 million, marking a year-over-year decrease of 9497.02%. This contributed to the annual value of -$234.7 million for FY2024, which is 6183.55% up from last year.
- As of Q4 2024, Summit Therapeutics' Income from Continuing Operations stood at -$65.6 million, which was down 8122.89% from -$60.8 million recorded in Q3 2024.
- In the past 5 years, Summit Therapeutics' Income from Continuing Operations ranged from a high of -$9.0 million in Q1 2020 and a low of -$65.6 million during Q4 2024
- Moreover, its 4-year median value for Income from Continuing Operations was -$20.5 million (2023), whereas its average is -$32.8 million.
- Per our database at Business Quant, Summit Therapeutics' Income from Continuing Operations crashed by 22950.72% in 2020 and then plummeted by 2096.81% in 2023.
- Summit Therapeutics' Income from Continuing Operations (Quarter) stood at -$9.0 million in 2020, then plummeted by 125.55% to -$20.3 million in 2022, then crashed by 78.38% to -$36.2 million in 2023, then tumbled by 81.23% to -$65.6 million in 2024.
- Its Income from Continuing Operations was -$65.6 million in Q4 2024, compared to -$60.8 million in Q3 2024 and -$36.2 million in Q4 2023.